Uveitis Treatment Market Share, Size, Growth, Opportunity and Forecast 2020-2025

*As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Uveitis Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

Market Overview:

The global uveitis treatment market grew at a CAGR of around 6% during 2014-2019. Uveitis treatment refers to various therapeutic procedures for treating inflammation in the uvea and surrounding tissues. The disease is characterized by blurred vision, dark or floating spots in the vision, redness of eye and sensitivity to light. Some of the commonly used uveitis treatment methods include topical, systemic and local corticosteroids, immunosuppressants, monoclonal antibodies, cycloplegic agents, antibiotics, analgesics and antivirals and antifungal medicines. These therapeutics are directed toward reducing inflammation, alleviating pain, preventing further tissue damage and restoring vision loss and can be used to treat conditions, including anterior uveitis, intermediate uveitis, posterior uveitis and panuveitis.

The increasing prevalence of optical infections and chronic eye disorders across the globe represents one of the key factors driving the growth of the market. Uveitis is highly prevalent among individuals suffering from diabetes, eye injuries, cataract, glaucoma, cystoid macular edema, band keratopathy and autoimmune and inflammatory disorders. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, the increasing awareness regarding the available treatment alternatives for managing uveitis has resulted in a significant increase in the demand for corticosteroid treatments among patients and healthcare providers. Additionally, various technological advancements in the treatment alternatives, such as the development of non-steroidal injectables and anti-tumor necrosis factor (TNF) drugs, are acting as other growth-inducing factors. These biological therapeutic agents are effective in the treatment of chronic uveitis and are administered as subcutaneous injections. Other factors, including the implementation of favorable initiatives by the governments to promote public health, along with improvements in the healthcare infrastructure, are anticipated to drive the market further. Looking forward, IMARC Group expects the global uveitis treatment market to continue its moderate growth during the next five years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global uveitis treatment market report, along with forecasts for growth at the global, regional and country level from 2020-2025. Our report has categorized the market based on region, Treatment Type, Disease Type, Cause and Distribution Channel.

Breakup by Treatment Type:

Corticosteroids
Immunosuppressant
Monoclonal Antibodies
Cycloplegic Agents
Antibiotics
Antivirals
Antifungal
Analgesics

Breakup by Disease Type:

Anterior Uveitis
Posterior Uveitis
Intermediate Uveitis
Panuveitis

Breakup by Cause:

Infectious
Non-infectious

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Breakup by Region:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc. and Santen Pharmaceutical Co. Ltd.

Key Questions Answered in This Report:

How has the global uveitis treatment market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global uveitis treatment market?
What are the key regional markets?
What is the breakup of the market based on the treatment type?
What is the breakup of the market based on the disease type?
What is the breakup of the market based on the cause?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global uveitis treatment market and who are the key players?
What is the degree of competition in the industry?